Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J; Poon, Hoifung; Deininger, Michael W; Collins, Robert; Swords, Ronan T; Watts, Justin; Pollyea, Daniel A; Medeiros, Bruno C; Traer, Elie; Tognon, Cristina E; Mori, Motomi; Druker, Brian J; Tyner, Jeffrey W.
Proc Natl Acad Sci U S A; 114(36): E7554-E7563, 2017 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-28784769